malaria | Benzinga
A long awaited trial verdict for SIGA Technologies (NASDAQ: SIGA) is poised to be revealed in the coming weeks, as investors are eager to see whether the company will hold on to exclusive rights for its lead drug, ST-246. ST-246 is the world's first treatment for smallpox, a potential bioterrism... Read More... Don't Miss Any Updates! News Directly in Your Inbox Subscribe to:
Source: benzinga.com